Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

DOI: https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 1373.

DOI: https://doi.org/10.1182/blood-2019-124030

Published: 2019

Journal Articles

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Ellen K. Ritchie, MD, David Cella, PhD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 1332.

DOI: https://doi.org/10.1182/blood-2019-123779

Published: 2019

Journal Articles

Combined Targeting of the Menin-MLL1 Chromatin Complex and FLT3 As a Novel Therapeutic Concept Against NPM1 Mutant or MLL -Rearranged AML with Mutated FLT3

Margarita M. Dzama, MSc, Martha C. Taubert, MSc, Kerstin Kunz, Johanna Rausch, MD, Chun-Wei David Chen, PhD, Annalisa Mupo, PhD, Patricia Hähnel, PhD, Matthias Theobald, MD PhD, Thomas Kindler, MD, Richard P. Koche, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Scott A. Armstrong, MD PhD, Michael W.M. Kühn, MD

Blood (2019) 134 (Supplement_1): 1441.

DOI: https://doi.org/10.1182/blood-2019-122847

Published: 2019

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

DOI: https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

DOI: https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

DOI: https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 910.

DOI: https://doi.org/10.1182/blood-2019-130694

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

DOI: https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Abhay Singh, MBBS, MPH, Sarah Sadek, MD, Mark G. Faber, DO, Jeffrey Baron, PharmD, James E. Thompson, MD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, Eunice S. Wang, MD, Swapna Thota, MD

Blood (2019) 134 (Supplement_1): 5095.

DOI: https://doi.org/10.1182/blood-2019-132040

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

DOI: https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Yuichi Ishikawa, MD PhD, Koichi Saito, PhD, Naomi Kawashima, MD PhD, Michie Morimoto, Hidetoshi Murao, PhD, Daisuke Terada, Takeshi Yamaura, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2672.

DOI: https://doi.org/10.1182/blood-2019-124632

Published: 2019

Journal Articles

Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations

Mary Figueroa, BS, Mansour Alfayez, MD, Yue Lu, PhD, Marcos Estecio, PhD, Seyed Javad Moghaddam, MD, Marina Y Konopleva, MD PhD, Elias Jabbour, MD, Courtney D. DiNardo, MDMSc, Joya Chandra, PhD

Blood (2019) 134 (Supplement_1): 2554.

DOI: https://doi.org/10.1182/blood-2019-127216

Published: 2019

Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 2564.

DOI: https://doi.org/10.1182/blood-2019-131635

Published: 2019

Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2019) 134 (Supplement_1): 2865.

DOI: https://doi.org/10.1182/blood-2019-130633

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

DOI: https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Development of Predictive Biomarker and Optimal Treatment Strategy with FLT3 Inhibitors in Acute Myeloid Leukemia

Jeong Hui Kim, Yasuhiko Harada, MD PhD, Yuichi Ishikawa, MD PhD, Naomi Kawashima, MD PhD, Marie Nakashima, MD, Yoko Ushijima, MD PhD, Takahiro Nishiyama, MD PhD, Tatsunori Goto, MD PhD, Nobuaki Fukushima, MD PhD, Rika Kihara, MD PhD, Tomohiro Kajiguchi, MD PhD, Koichi Watamoto, MD PhD, Akio Kohno, MD PhD, Kunio Kitamura, MD PhD, Yukiyasu Ozawa, MD PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 1418.

DOI: https://doi.org/10.1182/blood-2019-127610

Published: 2019

Journal Articles

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Ayako Nogami, MD PhD BPharm, Daisuke Watanabe, MD, Keigo Okada, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Toshikage Nagao, MD, PhD, Shuji Tohda, MD, PhD, Osamu Miura, MD, PhD

Blood (2019) 134 (Supplement_1): 1425.

DOI: https://doi.org/10.1182/blood-2019-123183

Published: 2019

Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH

Blood (2019) 134 (Supplement_1): 3910.

DOI: https://doi.org/10.1182/blood-2019-127416

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

DOI: https://doi.org/10.1182/blood-2019-123819

Published: 2019

NARROW

How I treat acute myeloid leukemia in the era of new drugs

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3 -Mutated ( FLT3 mut+ ) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

Combined Targeting of the Menin-MLL1 Chromatin Complex and FLT3 As a Novel Therapeutic Concept Against NPM1 Mutant or MLL -Rearranged AML with Mutated FLT3

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Development of Predictive Biomarker and Optimal Treatment Strategy with FLT3 Inhibitors in Acute Myeloid Leukemia

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only